Novo inks $4.7B Akero buyout to bag late-phase MASH prospect
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown…
89bio was left between a Roche and a hard place in buyout talks
Everyone flirted with 89bio. Only Roche wanted to put a ring on it. In a financial filing, 89bio detailed…
Roche becomes MASH player via $3.5B deal for 89bio, phase 3 drug
Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
F. Hoffmann-La Roche Ltd 89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated…
MASH dash speeds up as Roche acquires 89bio for up to $3.5B
The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a…
Roche poised to buy MASH drug developer 89bio for $3.5bn
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and…
Roche acquires 89bio for US$3.5bn
Under the agreement, swiss Roche AG will pay US$14.50 per share in cash, equal to an equity value…